menu
Orano Med chooses The Hive for its new site
Kadans, a leading player in real estate development dedicated to innovative ecosystems in Europe, announces the signing of a new lease with Orano Med. This subsidiary of the Orano Group, specialising in the development of targeted alpha therapies in oncology, will establish its headquarters and new research and development (R&D) laboratory within The Hive at Campus Grand Parc in Villejuif.
The fit-out works will precede the arrival of the teams, scheduled for 2026. With this new location, Orano Med is integrating into a rapidly developing innovation district, centred around the Villejuif – Gustave Roussy station (lines M14 and M15) and is driven by the Paris Saclay Cancer Cluster (PSCC), France’s first biocluster dedicated to oncology.
The research laboratory, due to be commissioned in the first half of 2026, will focus on the development of chemical vectors for applications in targeted alpha therapy. It will strengthen Orano Med’s R&D capacities and accelerate the in-house development of innovative new cancer therapies. This new site continues Orano Med’s investment strategy in France.
Within this ecosystem, Orano Med will be based in The Hive, a 25,000 m² hub designed and operated by Kadans Science Partner, a leading European player in cutting-edge scientific real estate. The Hive will host key innovators in oncology research, shaping the diagnostics, treatments, and prevention strategies of tomorrow. Orano Med will join companies such as Orakl Oncology and Sanofi at The Hive.
Sophie Letournel, Head of Strategy, Programs and Portfolio at Orano Med, said:
“Our move into The Hive in Villejuif will strengthen our ability to develop innovative alpha therapies and accelerate oncology research, while positioning us at the heart of a French ecosystem of excellence dedicated to innovation in this field.”
Elsa Ferrard, Director of Kadans Science Partner France, commented:
“We are very proud to welcome Orano Med. It is an outstanding company that confirms the attractiveness of the site for innovative oncology biotechs.”
Benjamin Garel, CEO of the Paris Saclay Cancer Cluster, added:
“Orano Med is one of the pioneers in radioligand therapy, one of the most promising modalities in targeted therapies, and we are delighted to welcome them at the heart of this oncology-dedicated cluster.”
About Orano Med
Orano Med, a subsidiary of the Orano Group, is a clinical-stage
biotechnology company which develops a new generation of targeted
therapies against cancer using the unique properties of lead-212 (212Pb),
an alpha-emitting radioisotope and one
of the more potent therapeutic payloads against cancer cells known
as Targeted Alpha-Emitter Therapy (TAT). AlphaMedix, its most advanced
asset in clinical development for GEP-NETs tumors, received Breakthrough
Designation from the FDA in 2024. The
company is advancing several potential treatments using 212Pb combined with various targeting agents through clinical and preclinical studies. Orano Med has 212Pb manufacturing facilities, laboratories, and R&D centers in
France and in the US. It is expanding its GMP-manufacturing capacities for 212Pb
radiolabeled pharmaceuticals in North America and Europe and building a
unique, independent, and fully integrated industrial platform to serve
the needs of
patients globally.
About Orano
As a recognized international leading operator in the field of nuclear
materials, Orano delivers solutions to address present and future global
energy and health challenges. Its expertise and mastery of cutting-edge
technologies enable Orano to offer its customers high value-added
products and services throughout the entire fuel cycle. Every day, the
Orano group’s 17,500 employees draw on their skills, unwavering
dedication to safety and constant quest for innovation, with the
commitment to develop know-how in the transformation and control of
nuclear materials, for the climate and for a healthy and
resource-efficient world, now and tomorrow.
Orano, giving nuclear energy its full value.
About Kadans Science Partner
Kadans Science Partner is a leading player in real estate development dedicated to innovative ecosystems in Europe. By designing, developing, and managing infrastructures tailored to the needs of businesses and researchers, Kadans fosters the growth of strategic sectors and supports the emergence of high-impact technological solutions.
Head Office
125 avenue de Paris
F-92320 Châtillon
Tel. : +33 (0)1 34 96 00 00
Fax : +33 (0)1 34 96 00 01
Press Contact
Sophie Letournel
Head of Strategy, Governance and Communications
sophie.letournel@orano.group
Tel. : +33 6 38 44 34 11